Edolac is indicated- For acute and long-term use in the management of signs and symptoms: Osteoarthritis, Rheumatoid arthritis For the management of acute pain Acute gout
Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5-50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.
Adults and over 18 years: Etodolac 300 mg capsule: 600 mg daily in 1-2 divided doses Etodolac 600 mg ER tablet: Once daily Pediatric: Safety and effectiveness in pediatric patients below the age of 18 years have not been established.
The common side effects of Edolac involve the gastrointestinal system. It can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, Gl ulcers, vomiting. Other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Etodolac is contraindicated in patients with known hypersensitivity to Etodolac. Etodolac should not be given to patients who have experienced asthma, urticaria or other allergic type reactions after taking Aspirin or other NSAIDs.
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. When Edolac is administered with Aspirin, its protein binding is reduced, although the clearance of free Edolac is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of Edolac and Aspirin is not generally recommended because of the potential of increased adverse effects.
Edolac should be given with caution in patients with severe hepatic reactions, pre existing asthma, fluid retention, hypertension or heart failure. If clinical sings and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash etc.), it should be discontinued.